DCTA
NEUTRALDirecta Plus CEO Buys Shares
The CEO of the specialty chemicals company has purchased additional shares in the business.
Directa Plus
15.25GBX
-1.61%
Market Cap
15.92M
Volume
17.82k
22% of avg
P/E Ratio
-5.08
EPS (TTM)
-0.03
Beta
0.66
Day Range
14.53p - 16.00p
52 Week Range
5.50p15.25p21.00p
15.25p
Upcoming Events
DCTA
NEUTRALDirecta Plus CEO Buys 50,000 Shares
The CEO of the graphene-based products manufacturer has purchased 50,000 shares in the company.
DCTA
NEUTRALDirecta Plus Director Increases Shareholding
The retailer announces a director has purchased additional shares in the company.
DCTA
NEUTRALDirecta Plus CEO Buys 25,000 Shares
The CEO of the specialty chemicals company has purchased 25,000 shares.
DCTA
NEUTRALDirecta Plus Plc Announces Investor Presentation
The specialty chemicals company is hosting a virtual investor presentation to discuss its recent financial results.
DCTA
NEUTRALDirecta Plus Plc Publishes Annual Report and AGM Notice
The specialty chemicals company has posted its annual report and notice of annual general meeting.
DCTA
BADDirecta Plus Reports Significant Revenue Decline and Increased Losses in 2024 Results
The graphene-based products manufacturer faced significant challenges, with revenue plummeting 37% and losses widening. Despite some positive signs in early 2025, ongoing market difficulties and operational inefficiencies paint a concerning picture.
DCTA
NEUTRALDirecta Plus Provides Update on Delayed Results Announcement
The specialty chemicals company has announced a delay in the release of its 2024 audited results, which are now expected in early June 2025.
DCTA
GOODDirecta Plus Secures €1.59 Million Contract Extension with OMV Petrom
The specialty chemicals company has secured a €1.59 million contract extension with a major energy operator, providing multi-year revenue visibility and supporting its growth in the oil & gas sector.
DCTA
BADDirecta Plus Plc Reports Widening Losses and Declining Revenues in FY2024
The specialty chemicals company reports widening losses and declining revenues in FY2024, with the need for cost savings and further senior appointments to address challenges.